ELIXIR part of new IMI project to improve security in drug development

eTransafe logo

ELIXIR is partner in eTRANSAFE, a new €40 million project funded by the Innovative Medicines Initiative (IMI), which began in September. The five-year project aims to develop an advanced data integration infrastructure and new computational methods to improve security in drug development process.

ELIXIR is part of the project consortium of 8 academic institutions, 6 SMEs and 12 pharmaceutical companies, coordinated by the Fundació Institut Mar d'Investigacions Mèdiques (IMIM, part of ELIXIR Spain) and led by the pharmaceutical company Novartis.

ELIXIR will be leading two main tasks: (1) creating a policy framework that allows industry and other organisations to share drug safety data and adhere to consistent guidelines for predictive toxicology models, and (2) data interoperability and integration. The technical and scientific work will be carried out in three ELIXIR Nodes: EMBL-EBI, ELIXIR Denmark (Technical University of Denmark) and ELIXIR Spain (through the Barcelona Supercomputing Centre and IMIM).

More information:

Tue 5 September 2017